Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. Gore ME, et al. Among authors: carteni g. Cancer. 2011 Feb 1;117(3):501-9. doi: 10.1002/cncr.25452. Epub 2010 Sep 22. Cancer. 2011. PMID: 20862748 Free article.
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Bajetta E, et al. Among authors: carteni g. Cancer. 2006 Nov 15;107(10):2474-81. doi: 10.1002/cncr.22272. Cancer. 2006. PMID: 17054107 Free article. Clinical Trial.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Motzer RJ, et al. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22. Lancet. 2008. PMID: 18653228 Clinical Trial.
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: carteni g. Anticancer Drugs. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293. Anticancer Drugs. 2009. PMID: 19262371 Clinical Trial.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. Di Lorenzo G, et al. Among authors: carteni g. Ann Oncol. 2009 Sep;20(9):1535-1542. doi: 10.1093/annonc/mdp025. Epub 2009 May 27. Ann Oncol. 2009. PMID: 19474115 Free article.
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S. Di Lorenzo G, et al. Among authors: carteni g. J Clin Oncol. 2009 Sep 20;27(27):4469-74. doi: 10.1200/JCO.2009.22.6480. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652053 Clinical Trial.
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Porta C, et al. Among authors: carteni g. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. BJU Int. 2011. PMID: 21599821
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. Grünwald V, et al. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. Eur J Cancer. 2012. PMID: 21803569 Clinical Trial.
140 results